Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520734 | 1.00 | HTR2C (0.51) | HTR2CHTR2AKDM4EALDH1A1HTR1A | |
| SCHEMBL15944077 | 0.88 | KDM4E (0.50) | HTR2CHTR2AKDM4EALDH1A1DRD2 | |
| SCHEMBL20024496 | 0.83 | HTR2C (0.43) | HTR2CHTR2AHTR1AHTR2BADRB2 | |
| SCHEMBL21266309 | 0.82 | ALDH1A1 (0.48) | HTR2CHTR2AKDM4EALDH1A1HTR1A | |
| SCHEMBL623211 | 0.79 | ADRB2 (0.66) | HTR2CHTR2AHTR1AHTR2BADRB2 | |
| SCHEMBL29702844 | 0.79 | ADRB2 (0.66) | HTR2CHTR2AHTR1AHTR2BADRB2 | |
| SCHEMBL248419 | 0.79 | AKR1C3 (0.46) | HTR2CHTR2AALDH1A1KMT2AICMT | |
| SCHEMBL18508879 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1DRD2SLC6A4ADRB2 | |
| SCHEMBL5923660 | 0.78 | ADRB2 (0.64) | HTR2CHTR2AKDM4EALDH1A1HTR1A | |
| SCHEMBL12113330 | 0.78 | GPR84 (0.62) | HTR2CHTR2AKDM4EALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | claimed |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2024-03-07 | — | — | US | claimed |
| WO-2023172497-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING COCAINE USE DISORDER | DREXEL UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| US-11744810-B2 | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2023-09-05 | — | — | US | claimed |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2022-07-28 | — | — | US | claimed |
| US-11266612-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DREXEL UNIVERSITY (US) | 2022-03-08 | — | — | US | claimed |
| US-20200397721-A1 | Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder | UNIV DREXEL (US) | 2020-12-24 | — | — | US | claimed |
| US-20200390728-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2020-12-17 | — | — | US | claimed |
| EP-3062791-B1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2020-01-08 | — | — | EP | claimed |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2018-04-05 | — | — | US | claimed |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2016-09-08 | — | — | US | claimed |
| EP-3062791-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | Drexel University (US) | 2016-09-07 | — | — | EP | claimed |
| WO-2015066019-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2015-05-07 | — | — | WO | claimed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | claimed |
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | HTR2C 3782/4885HTR2A 3926/4885KDM4E 3113/4885 |
| US-20200390728-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | HTR2C 84/4885HTR2A 129/4885KDM4E 4017/4885 |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, COMT, SLC6A2 | HTR2C 138/4885HTR2A 71/4885KDM4E 3034/4885 |
| US-11266612-B2 | D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease | DRD3, PARK7, SLC6A3 | HTR2C 88/4885HTR2A 121/4885KDM4E 4081/4885 |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | HTR2C 84/4885HTR2A 129/4885KDM4E 4017/4885 |
| US-20200397721-A1 | Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder | CHAT, COMT, SLC6A2 | HTR2C 138/4885HTR2A 71/4885KDM4E 3034/4885 |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | HTR2C 180/4885HTR2A 82/4885KDM4E 2884/4885 |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | HTR2C 180/4885HTR2A 82/4885KDM4E 2884/4885 |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | CES2, CHAT, SLC18A2 | HTR2C 31/4885HTR2A 51/4885KDM4E 917/4885 |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | HTR2C 3782/4885HTR2A 3926/4885KDM4E 3113/4885 |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | HTR2C 84/4885HTR2A 129/4885KDM4E 4017/4885 |
| US-11744810-B2 | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | CHAT, COMT, SLC6A2 | HTR2C 138/4885HTR2A 71/4885KDM4E 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.